Investing

Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on EPS By Investing.com


© Reuters. After-Hours Movers: Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on EPS

After-Hours Stock Movers:

Spectrum Pharmaceuticals (NASDAQ:) 28% LOWER; The FDA’s Oncologic Drugs Advisory Committee (ODAC) met to review poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 20 insertion mutations. The committee voted 9-4 that the current benefits of poziotinib did not outweigh its risks.

Avenue Therapeutics, Inc. (NASDAQ:) 24% HIGHER; announced that it will effect a 1-for-15 reverse split of its common stock.

Cano Health Inc (NYSE:) 5% HIGHER; adds to 32% intra-day gains on reports it is for sale with multiple bidders.

CalAmp Corp (NASDAQ:) 4% HIGHER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $72.8 million versus the consensus estimate of $69.27 million.

Costco (NASDAQ:) 3% LOWER; reported Q4 EPS of $4.20, $0.05 better than the analyst estimate of $4.15. Revenue for the quarter came in at $72.09 billion versus the consensus estimate of $71.64 billion.

Guidewire (NYSE:) 3% HIGHER; announced that its board of directors approved a share repurchase program with authorization to purchase up to $400.0 million of its outstanding shares of Common Stock, effective immediately.

Trevi Therapeutics, Inc. (NASDAQ:) 2% LOWER; commenced an underwritten public offering of shares of its common stock.


Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button